Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: George T. Santamaria who wrote (4371)	5/22/1998 9:34:00 AM
From: Bhag Karamchandani	Read Replies (2) \| Respond to of 6136

"what value do you give to the organization that designed the drug but did not appreciate it's potential enough to take it commercial". Big guys make big mistakes and yet quite a few of them survive. Look at IBM, Apple, ... I have previously lauded AGPH for their efficacy in getting Viracept approved in record time and their highly successful marketing efforts. By the way, over seven years ago Barron's had a table of biotech companies including AGPH. It was shown as having six drugs at various stages of trial and development. Today, there are only two or three that are on any realistic time line. Their science was supposed to avoid the very thing that they are perceived as being, today- a single drug company. I remain a patient admirer of AGPH. I believe the stock is undervalued, but, ten years of R&D has yet to earn a dime, much less pay for itself. The classic question used to be where are the investors yachts, in relation to brokers. May be the revised questions should be where are the investors yachts in relation to the insiders who are able to cash out their shares.